Immunological Response to COVID-19 Vaccine Boosters in Multiple Sclerosis Patients Treated with anti-CD20 Therapy

被引：0
|
作者：
De Oliveira, Antonia [1 ]
Lei, Joyce [1 ]
Liu, Jiayuan [1 ]
Roche, Morgan [1 ]
Lin, Jerry [1 ]
Alfonso, Roberto [2 ]
Sadiq, Saud [1 ]
机构：
[1] Tisch Multiple Sclerosis Res Ctr New York, New York, NY USA
[2] Tisch Multiple Sclerosis, New York, NY USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202245
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S21.001
引用
收藏
页数：3
相关论文
共 50 条
  • [1] COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
    Meca-Lallana, Virginia
    Aguirre, Clara
    Rio, Beatrizdel
    Cardenoso, Laura
    Alarcon, Teresa
    Vivancos, Jose
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44
  • [2] Response to COVID-19 mRNA Vaccination in Patients with Multiple Sclerosis on anti-CD20 Disease Modifying Therapies
    Wolf, Andrew
    Pratt, Robert W.
    Crooks, Kristy
    Borko, Tyler
    Gonzalez, Jose Parra
    Vollmer, Timothy
    Frazer-Abel, Ashley
    ANNALS OF NEUROLOGY, 2021, 90 : S179 - S180
  • [3] Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications
    Moser, T.
    Otto, F.
    Pilz, G.
    Wipfler, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 395 - 395
  • [4] Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists
    Kant, Sam
    Kronbichler, Andreas
    Salas, Antonio
    Bruchfeld, Annette
    Geetha, Duvuru
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (05): : 1197 - 1199
  • [5] Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?
    Avasarala, Jagannadha
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [6] Anti-CD20 disease modifying therapies decrease the humoral response to COVID-19 mRNA vaccination in patients with multiple sclerosis
    Wolf, A.
    Pratt, R.
    Crooks, K.
    Borko, T.
    Gonzalez, J. Parra
    Vollmer, T.
    Frazer-Abel, A.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 581 - 581
  • [7] Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
    Sand, Ilana Katz
    Gnjatic, Sacha
    Krammer, Florian
    Tuballes, Kevin
    Carreno, Juan Manuel
    Satyanarayan, Sammita
    Filomena, Susan
    Staker, Erin
    Tcheou, Johnstone
    Miller, Aaron
    Fabian, Michelle
    Safi, Neha
    Nichols, Jamie
    Patel, Jasmin
    Krieger, Stephen
    Tankou, Stephanie
    Horng, Sam
    Klineova, Sylvia
    Beck, Erin
    Merad, Miriam
    Lublin, Fred
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [8] Development of anti-CD20 therapy for multiple sclerosis
    Bartok, Beatrix
    Silverman, Gregg J. J.
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1312 - 1318
  • [9] Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed
    Moghadasi, Abdorreza Naser
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [10] Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19
    Wilber, Eli
    Piantadosi, Anne
    Babiker, Ahmed
    McLendon, Kaleb
    O'Sick, William
    Fitts, Eric
    Webster, Andrew S.
    Verkerke, Hans
    Kim, James S.
    Phadke, Varun K.
    Rouphael, Nadine
    Titanji, Boghuma K.
    Blake, William T.
    Howard-Anderson, Jessica
    Roback, John D.
    Lam, Wilbur A.
    Damhorst, Gregory L.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (08):
12345